Calidi Biotherapeutics, Inc. (CLDI) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Calidi Biotherapeutics reported revenue of $0. Net income was -$19.9M, or -$95.20 per diluted share. Operating activities generated -$21.3M of cash, leaving -$21.3M of free cash flow. At fiscal year end, Calidi Biotherapeutics held $8.9M in total assets against $5.1M in total liabilities.
Open the full interactive Calidi Biotherapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Calidi Biotherapeutics Key Stats
| Share Price | $0.90 |
|---|---|
| Market Cap | $1.3M |
| 52-Week Range | $0.90 – $26.72 |
| Shares Outstanding | 1.4 million (basic, 2026 Q2) |
Calidi Biotherapeutics Income Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Revenue | $0 | — | $0 | $0 |
| Operating Income | -$4.7M | -$29.0M | -$21.8M | -$20.2M |
| Pre-Tax Income | $3.9M | -$29.2M | -$22.2M | -$20.0M |
| Income Tax | $346,987 | $16,000 | $14,000 | $15,000 |
| Net Income | $3.5M | -$29.2M | -$22.1M | -$19.9M |
| Diluted EPS | $345.60 | $3321.60 | -$570.24 | -$95.20 |
Calidi Biotherapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$5.1M | -$4.0M | -$4.1M | -$4.2M |
| Diluted EPS | -$35.36 | -$0.93 | -$6.88 | -$2.94 |
Calidi Biotherapeutics Balance Sheet
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash & Equivalents | — | — | $9.6M | — |
| Current Assets | $401,671 | $4.3M | $10.2M | $6.3M |
| Total Assets | $42.9M | $10.0M | $14.2M | $8.9M |
| Current Liabilities | $4.5M | $10.2M | $9.5M | $3.9M |
| Total Long-Term Debt | — | $2.1M | $3.8M | $600,000 |
| Total Liabilities | $5.6M | $18.3M | $12.2M | $5.1M |
| Shareholders' Equity | -$5.2M | -$8.2M | $1.5M | $3.8M |
Calidi Biotherapeutics Cash Flow Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash From Operations | $98,051 | -$27.0M | -$19.7M | -$21.3M |
| Cash From Investing | $187.7M | -$478,000 | -$16,000 | -$170,000 |
| Cash From Financing | -$188.8M | $29.0M | $27.4M | $17.5M |
| Free Cash Flow | — | -$27.0M | -$19.7M | -$21.3M |
Figures from Calidi Biotherapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Calidi Biotherapeutics financials page for every line item.
Calidi Biotherapeutics Company Profile
| Ticker | CLDI |
|---|---|
| Exchange | NYSE, OTC |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | San Diego, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001855485 |
Frequently Asked Questions
What was Calidi Biotherapeutics' revenue in fiscal 2025?
Calidi Biotherapeutics (CLDI) reported revenue of $0 for fiscal 2025.
What is Calidi Biotherapeutics' annual revenue history?
Calidi Biotherapeutics' annual revenue by fiscal year: 2022: $0; 2024: $0; 2025: $0.
What was Calidi Biotherapeutics' net income in fiscal 2025?
Calidi Biotherapeutics reported net income of -$19.9M for fiscal 2025.
What was Calidi Biotherapeutics' earnings per share (EPS) in fiscal 2025?
Calidi Biotherapeutics' diluted EPS was -$95.20 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Calidi Biotherapeutics generate in fiscal 2025?
Calidi Biotherapeutics generated -$21.3M of free cash flow in fiscal 2025.
What was Calidi Biotherapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Calidi Biotherapeutics reported revenue of $0.
How much debt does Calidi Biotherapeutics have?
Calidi Biotherapeutics reported $600,000 of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Calidi Biotherapeutics are outstanding?
Calidi Biotherapeutics reported a weighted average of 1.4 million basic shares outstanding in 2026 Q2.
What is Calidi Biotherapeutics' market cap?
Based on its latest closing price, Calidi Biotherapeutics (CLDI) has a market capitalization of about $1.3M.
When does Calidi Biotherapeutics' fiscal year end?
Calidi Biotherapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Calidi Biotherapeutics headquartered?
Calidi Biotherapeutics lists its business address in San Diego, California in its SEC filings.
Calidi Biotherapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →